Clinica Baviera (CBAV) AI Stock Analysis

• Market Cap: €694.53M
• Dividend Yield: 3.69%
• Average Volume (3M): 2.49K
• Price to Earnings (P/E): 17.1
• Beta (1Y): 0.40
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: ES
• Employees: 1,706
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.62
• Shares Outstanding: 16,307,580
• 10 Day Avg. Volume: 1,694
• 30 Day Avg. Volume: 2,494
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €51.00
• Price Target Upside: 20.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: €44.00 ▲(4.27% Upside)

Clinica Baviera's strong financial performance is a significant positive, with robust profitability and effective cash flow management. However, the technical analysis indicates bearish momentum, which is a concern. The valuation is reasonable, but not compelling enough to offset the negative technical indicators. Overall, the stock presents a mixed outlook with strong financials but weak technical signals.

Clinica Baviera Business Overview & Revenue Model

Company Description

Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, vías lagrimales, and oculoplasty treatments. It operates approximately 90 centers in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.

How the Company Makes Money

Clinica Baviera generates revenue primarily through its surgical and medical services, including LASIK and cataract surgeries, as well as consultations and follow-up care. The clinic charges patients directly for these services, which are often covered by private health insurance plans. Additionally, CBAV may have partnerships with insurance companies that provide coverage for its procedures, further widening its patient base. The company also engages in marketing and promotional activities to attract new patients and foster brand loyalty, which plays a significant role in driving its revenue growth.

Clinica Baviera Financial Statement Overview

Summary

Clinica Baviera demonstrates strong financial health with robust profitability, efficient operations, and effective cash flow management. The company maintains a low leverage position, enhancing its financial stability. While revenue growth has slowed, the company continues to generate strong returns on equity and manage its cash flows effectively.

Income Statement

Clinica Baviera shows strong profitability with a consistent gross profit margin above 80% and a healthy net profit margin around 14% to 16%. The revenue growth rate is positive, indicating steady growth, although it has slowed compared to previous years. EBIT and EBITDA margins are robust, reflecting efficient operations.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.10 in the TTM period, indicating low leverage and financial stability. Return on equity is strong at over 40%, showcasing effective use of equity to generate profits. The equity ratio is healthy, suggesting a solid capital structure.

Cash Flow

Clinica Baviera exhibits strong cash flow management with a significant free cash flow growth rate of 57% in the TTM period. The operating cash flow to net income ratio is above 1, indicating good cash generation relative to net income. Free cash flow to net income ratio is also solid, reflecting efficient cash utilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	285.85M	262.65M	224.92M	198.45M	172.73M	122.63M
Gross Profit	229.76M	232.08M	197.85M	172.95M	151.25M	107.37M
EBITDA	80.46M	78.11M	67.22M	56.15M	53.49M	34.06M
Net Income	39.10M	40.20M	35.97M	29.52M	27.39M	13.94M
Balance Sheet
Total Assets	222.25M	211.95M	178.64M	150.10M	133.81M	120.92M
Cash, Cash Equivalents and Short-Term Investments	40.16M	38.58M	51.24M	38.99M	32.27M	26.94M
Total Debt	8.94M	63.47M	47.41M	39.98M	51.56M	54.84M
Total Liabilities	130.71M	113.59M	86.37M	81.74M	78.42M	76.02M
Stockholders Equity	90.54M	96.92M	91.00M	67.34M	54.60M	44.49M
Cash Flow
Free Cash Flow	42.11M	36.25M	35.13M	39.35M	36.28M	23.64M
Operating Cash Flow	66.88M	62.76M	57.81M	53.38M	46.86M	31.46M
Investing Cash Flow	-12.35M	-20.90M	-44.31M	-12.56M	-17.08M	-21.40M
Financing Cash Flow	-53.11M	-39.91M	-24.37M	-31.45M	-30.80M	-3.15M

Clinica Baviera Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 42.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Negative. The current price of 42.2 is below the 20-day moving average (MA) of 44.24, below the 50-day MA of 44.32, and above the 200-day MA of 37.53, indicating a neutral trend. The MACD of -0.58 indicates Positive momentum. The RSI at 27.34 is Positive, neither overbought nor oversold. The STOCH value of 10.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:CBAV.

Clinica Baviera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	73 Outperform	1.32B	12.47	15.34%	4.26%	11.04%	8.29%
PRM	73 Outperform	227.96M	―	8.47%	3.17%	―	―
CBAV	65 Neutral	€694.53M	17.08	―	3.69%	―	―
RJF	64 Neutral	230.31M	34.73	4.85%	1.71%	0.58%	-30.60%
ATRY	51 Neutral	205.14M	-6.62	-12.55%	―	5.54%	30.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Clinica Baviera Corporate Events

Clínica Baviera Shareholders Approve Key Proposals at General Meeting

The Ordinary General Meeting of Shareholders of Clínica Baviera, S.A. approved all proposals by the Board of Directors, with 86.36% of the share capital represented. Key decisions included the approval of the annual accounts, management report, non-financial information statement, and sustainability report for 2024, as well as the re-election of Forvis Mazars Auditores as auditor for 2025. These approvals reflect strong shareholder support and are expected to positively impact the company’s governance and operational transparency.

Clínica Baviera Appoints New Vice Presidents to Board

Clínica Baviera has announced the appointment of Ms. Yongmei Zhang and Mr. Eduardo Baviera Sabater as vice presidents of its Board of Directors. This strategic leadership change is expected to enhance the governance structure of the company, potentially impacting its strategic direction and stakeholder engagement.